AAV-DJ介导MYOC沉默治疗MYOC相关青光眼
该研究在携带MYOCP370L突变的转基因青光眼小鼠模型中,经玻璃体腔注射AAV-DJ载体递送靶向MYOC的短发夹RNA(shMYOC)。治疗显著减少小梁网肌纤蛋白蓄积与内质网应激,阻止年轻小鼠眼压随龄升高,并保护视网膜神经节细胞存活与视功能;在老年小鼠中同样降低眼压并改善房水流出易度。
要点
- AAV-DJ-shMYOC可减少小梁网肌纤蛋白蓄积及内质网应激标志物。
- 年轻Tg-MYOCP370L小鼠中可预防年龄相关眼压升高并维持视功能。
- 老年Tg-MYOCP370L小鼠中仍可降低眼压并改善房水流出易度。
核心结论
- AAV-DJ介导的MYOC沉默可减轻Tg-MYOCP370L小鼠的青光眼病理改变,提示其作为肌纤蛋白相关青光眼基因治疗策略的潜力。
研究设计与样本
- 在MYOCP370L转基因青光眼小鼠模型(Tg-MYOCP370L)中评估AAV-DJ载体递送shMYOC的治疗效果。
- 采用经瞳孔玻璃体腔途径注射AAV-DJ载体,该载体因高转导效率及对小梁网(TM)的嗜性而被选用。
- 治疗后评估肌纤蛋白蓄积、内质网应激标志物表达、眼压、房水流出易度、视网膜神经节细胞(RGC)存活及视功能。
主要发现
- AAV-DJ-shMYOC显著减少体内TM细胞中肌纤蛋白蓄积与内质网应激标志物。
- 在年轻Tg-MYOCP370L小鼠中有效预防年龄相关眼压升高、保留房水流出易度并维持RGC存活与视功能。
- 在老年Tg-MYOCP370L小鼠中,AAV-DJ介导的MYOC沉默同样降低眼压并改善流出易度。
临床怎么用
- 结果支持在MYOC突变相关开角型青光眼中探索AAV-DJ递送shMYOC的基因治疗方向。
- 治疗靶点聚焦小梁网肌纤蛋白蓄积与内质网应激通路,可能同时影响眼压与房水流出易度。
局限性
- 证据仅来自Tg-MYOCP370L小鼠模型,尚未在人体中验证。
- 原文摘要未报告样本量、具体数值、统计显著性及长期安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the therapeutic efficacy of an adeno-associated virus serotype DJ (AAV-DJ) vector delivering MYOC-targeting short-hairpin RNA (shMYOC) in a MYOCP370L transgenic glaucoma mouse model (Tg-MYOCP370L) for the treatment of open-angle glaucoma (OAG) associated with MYOC mutations. METHODS: An AAV-DJ vector, selected for its high transduction efficiency and tropism for trabecular meshwork (TM), was used to deliver shMYOC via a transpupillary intravitreal approach in Tg-MYOCP370L mice. Post-treatment evaluations included myocilin accumulation, ER stress marker expression, intraocular pressure (IOP), aqueous humor outflow facility, retinal ganglion cell (RGC) survival, and visual function. RESULTS: AAV-DJ-shMYOC markedly reduced myocilin accumulation and ER stress markers in TM cells in vivo, effectively preventing age-dependent IOP elevation, preserving aqueous humor outflow facility, and maintaining RGC survival and visual function in young Tg-MYOCP370L mice. In aged Tg-MYOCP370L mice, AAV-DJ-mediated MYOC silencing similarly lowered IOP and improved outflow facility. CONCLUSIONS: AAV-DJ-mediated MYOC silencing effectively alleviated glaucomatous pathology in Tg-MYOCP370L mice, highlighting its potential as a gene therapy strategy for myocilin-associated glaucoma.
引用
- Wan Y, Liu X, Yan X, et al. AAV-DJ-Mediated MYOC Silencing as a Gene Therapy Approach for Myocilin-Associated Glaucoma. Invest Ophthalmol Vis Sci. 2026. PMID: 41569028. doi:10.1167/iovs.67.1.48
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。